Alternative pathways for angiotensin II generation in the cardiovascular system

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 9, 2011, Pages 914-919

  Becari, C ^a   Oliveira, E B ^a   Salgado, M C O ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alternative pathway; Angiotensin II; Angiotensin converting enzyme; Rat elastase 2; Renin angiotensin system

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELASTASE; ELASTASE II; UNCLASSIFIED DRUG;

CARDIOVASCULAR SYSTEM; HEART; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY; LUNG; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

MUS; RATTUS;

EID: 80053306656     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2011007500093     Document Type: Review

References (57)

1. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
2. Zager PG, Luetscher JA. Effects of angiotensin III and ACTH on aldosterone secretion. Clin Exp Hypertens A 1982; 4: 1481-1504.
3. Albiston AL, Mustafa T, McDowall SG, Mendelsohn FA, Lee J, Chai SY. AT4 receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement. Trends Endocrinol Metab 2003; 14: 72-77.
4. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-33243.
5. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzymerelated carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
6. Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, et al. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 165: 196-203.
7. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155-163.
8. Swanson GN, Hanesworth JM, Sardinia MF, Coleman JK, Wright JW, Hall KL, et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept 1992; 40: 409-419.
9. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, et al. Angiotensin receptors. J Hypertens Suppl 1996; 14: S95-S103.
10. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003; 100: 8258-8263.
11. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002; 16: 149-160.
12. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302.
13. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354: 9-12.
14. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988; 77: I-4-I-13.
15. Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med 2008; 86: 615-621.
16. Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000; 101: 844-846.
17. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226.
18. Wei CC, Ferrario CM, Brosnihan KB, Farrell DM, Bradley WE, Jaffa AA, et al. Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo. J Pharmacol Exp Ther 2002; 300: 324-329.
19. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987; 79: 1-6.
20. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997; 273: H1769-H1774.
21. Takai S, Sakaguchi M, Jin D, Yamada M, Kirimura K, Miyazaki M. Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta 2001; 305: 191-195.
22. Boucher R, Demassieux S, Garcia R, Genest J. Tonin, angiotensin II system. A review. Circ Res 1977; 41: 26-29.
23. Cornish KG, Joyner WL, Gilmore JP. Direct evidence for the presence of a different converting enzyme in the hamster cheek pouch. Circ Res 1979; 44: 540-544.
24. Trachte GJ, Lefer AM. Inotropic and vasoactive effects of the naturally occurring angiotensins in isolated cat cardiac muscle and coronary arteries. Res Commun Chem Pathol Pharmacol 1979; 25: 419-427.
25. Cornish KG, Joyner WL, Gilmore JP. Evidence for the conversion of angiotensin I to angiotensin II by the coronary microcirculation. Blood Vessels 1979; 16: 241-246.
26. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984; 2: 277-284.
27. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-890.
28. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
29. Le Trong H, Neurath H, Woodbury RG. Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc Natl Acad Sci U S A 1987; 84: 364-367.
30. Arakawa K. Serine protease angiotensin II systems. J Hypertens Suppl 1996; 14: S3-S7.
31. Maruta H, Arakawa K. Confirmation of direct angiotensin formation by kallikrein. Biochem J 1983; 213: 193-200.
32. Tonnesen MG, Klempner MS, Austen KF, Wintroub BU. Identification of a human neutrophil angiotension II-generating protease as cathepsin G. J Clin Invest 1982; 69: 25-30.
33. Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun 1987; 149: 1186-1192.
34. Paula CA, Sousa MV, Salgado MC, Oliveira EB. Purification and substrate specificity of an angiotensin converting elastase-2 from the rat mesenteric arterial bed perfusate. Biochim Biophys Acta 1998; 1388: 227-238.
35. Santos CF, Paula CA, Salgado MC, Oliveira EB. Kinetic characterization and inhibition of the rat MAB elastase-2, an angiotensin I-converting serine protease. Can J Physiol Pharmacol 2002; 80: 42-47.
36. McDonald JE, Padmanabhan N, Petrie MC, Hillier C, Connell JM, McMurray JJ. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ACE production of angiotensin II in humans. Circulation 2001; 104: 1805-1808.
37. Richard V, Hurel-Merle S, Scalbert E, Ferry G, Lallemand F, Bessou JP, et al. Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation 2001; 104: 750-752.
38. Santos CF, Caprio MA, Oliveira EB, Salgado MC, Schippers DN, Munzenmaier DH, et al. Functional role, cellular source, and tissue distribution of rat elastase-2, an angiotensin IIforming enzyme. Am J Physiol Heart Circ Physiol 2003; 285: H775-H783.
39. Becari C, Sivieri DO Jr, Santos CF, Moyses MK, Oliveira EB, Salgado MC. Role of elastase-2 as an angiotensin II-forming enzyme in rat carotid artery. J Cardiovasc Pharmacol 2005; 46: 498-504.
40. Urata H, Nishimura H, Ganten D, Arakawa K. Angiotensinconverting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Blood Press Suppl 1996; 2: 22-28.
41. Waldeck K, Lindberg BF, Persson K, Andersson KE. Characterization of angiotensin II formation in human isolated bladder by selective inhibitors of ACE and human chymase: a functional and biochemical study. Br J Pharmacol 1997; 121: 1081-1086.
42. Bastos M, Maeji NJ, Abeles RH. Inhibitors of human heart chymase based on a peptide library. Proc Natl Acad Sci U S A 1995; 92: 6738-6742.
43. Hoit BD, Shao Y, Kinoshita A, Gabel M, Husain A, Walsh RA. Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J Clin Invest 1995; 95: 1519-1527.
44. Mangiapane ML, Rauch AL, MacAndrew JT, Ellery SS, Hoover KW, Knight DR, et al. Vasoconstrictor action of angiotensin I-convertase and the synthetic substrate (Pro11, DAla12)-angiotensin I. Hypertension 1994; 23: 857-860.
45. Garrison EA, Champion HC, Kadowitz PJ. [Pro11, D-Ala12] angiotensin I has rapid onset vasoconstrictor activity in the cat. Am J Physiol 1997; 273: E1059-E1064.
46. Nishimura H, Buikema H, Baltatu O, Ganten D, Urata H. Functional evidence for alternative ANG II-forming pathways in hamster cardiovascular system. Am J Physiol 1998; 275: H1307-H1312.
47. Inoue K, Nishimura H, Kubota J, Kawamura K. Alternative angiotensin II formation in rat arteries occurs only at very high concentrations of angiotensin I. Hypertension 1999; 34: 525-530.
48. Murakami M, Matsuda H, Kubota E, Wakino S, Honda M, Hayashi K, et al. Role of angiotensin II generated by angiotensin converting enzyme-independent pathways in canine kidney. Kidney Int Suppl 1997; 63: S132-S135.
49. Kunori Y, Muroga Y, Iidaka M, Mitsuhashi H, Kamimura T, Fukamizu A. Species differences in angiotensin II generation and degradation by mast cell chymases. J Recept Signal Transduct Res 2005; 25: 35-44.
50. Oliveira EB, Salgado MC, Turner AJ. A survey of vasoactive peptide metabolizing enzymes in the rat mesenteric arterial bed perfusate. Biochem Pharmacol 1991; 42: 1897-1904.
51. Santos CF, Oliveira EB, Salgado MC, Greene AS. Molecular cloning and sequencing of the cDNA for rat mesenteric arterial bed elastase-2, an angiotensin II-forming enzyme. J Cardiovasc Pharmacol 2002; 39: 628-635.
52. MacDonald RJ, Stary SJ, Swift GH. Rat pancreatic ribonuclease messenger RNA. The nucleotide sequence of the entire mRNA and the derived amino acid sequence of the pre-enzyme. J Biol Chem 1982; 257: 14582-14585.
53. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell alpha-and beta-chymases. Biochim Biophys Acta 2000; 1480: 245-257.
54. Wintroub BU, Schechter NB, Lazarus GS, Kaempfer CE, Schwartz LB. Angiotensin I conversion by human and rat chymotryptic proteinases. J Invest Dermatol 1984; 83: 336-339.
55. Santos CF, Greene AS, Salgado MC, Oliveira EB. Conversion of renin substrate tetradecapeptide to angiotensin II by rat MAB elastase-2. Can J Physiol Pharmacol 2004; 82: 1000-1005.
56. Becari C, Teixeira FR, Oliveira EB, Salgado MC. Angiotensinconverting enzyme inhibition augments the expression of rat elastase-2, an angiotensin II-forming enzyme. Am J Physiol Heart Circ Physiol 2011; May 20 [Epub ahead of print; doi:10.1152/ajpheart.00534.2010].
57. Becari C, Pereira HJV, Sivieri DO Jr, Mesquita JR, Oliveira EB, Salgado MCO. Angiotensin (1-12) metabolism in cardiac perfusate of wistar and spontaneously hypertensive rats. Washignton: Hypertension, 56: 2010. p e50-e116.